Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Equus caballus | Ferritin light chain | Starlite/ChEMBL | No references |
Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 43.9 % |
Echinococcus multilocularis | expressed protein | Ferritin light chain | 175 aa | 146 aa | 30.1 % |
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 44.4 % |
Echinococcus granulosus | expressed protein | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 142 aa | 29.6 % |
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Schistosoma japonicum | Ferritin, putative | Ferritin light chain | 175 aa | 144 aa | 24.3 % |
Brugia malayi | Hypothetical 65.5 kDa Trp-Asp repeats containing protein F02E8.5 inchromosome X | geminin, DNA replication inhibitor | 209 aa | 176 aa | 27.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | intermediate filament protein | 0.0033 | 0.0892 | 0.2772 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 0.3217 | 1 |
Echinococcus multilocularis | lamin dm0 | 0.0033 | 0.0892 | 0.0892 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0055 | 0.2092 | 0.6502 |
Echinococcus granulosus | lamin dm0 | 0.0033 | 0.0892 | 0.0892 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.2092 | 0.1318 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 0.3217 | 0.3217 |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0017 | 0.0092 | 0.0285 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 0.0892 | 0.2772 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 1 | 1 |
Onchocerca volvulus | 0.0033 | 0.0892 | 0.5 | |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3217 | 0.2553 |
Echinococcus granulosus | lamin | 0.0033 | 0.0892 | 0.0892 |
Echinococcus multilocularis | lamin | 0.0033 | 0.0892 | 0.0892 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.2092 | 0.2092 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3217 | 0.2553 |
Brugia malayi | TAR-binding protein | 0.0076 | 0.3217 | 1 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.2092 | 0.2092 |
Echinococcus multilocularis | musashi | 0.0033 | 0.0892 | 0.0892 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.2092 | 0.1318 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3217 | 0.2553 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.2092 | 0.1318 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.2092 | 0.2092 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 0.3217 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.086 | 0.2674 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 0.3217 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3217 | 0.2553 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0033 | 0.0892 | 0.2561 |
Echinococcus granulosus | intermediate filament protein | 0.0033 | 0.0892 | 0.0892 |
Onchocerca volvulus | 0.0033 | 0.0892 | 0.5 | |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3217 | 0.2553 |
Brugia malayi | intermediate filament protein | 0.0033 | 0.0892 | 0.2561 |
Echinococcus multilocularis | geminin | 0.0205 | 1 | 1 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.2092 | 0.2092 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0033 | 0.0892 | 0.2772 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 0.3217 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 1 | 1 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0055 | 0.2092 | 0.64 |
Brugia malayi | RNA binding protein | 0.0076 | 0.3217 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 0.3217 | 0.3217 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.5174 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | = 12.5893 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 22.3872 um | PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | 31.6228 uM | PUBCHEM_BIOASSAY: qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1484, AID504370, AID504374, AID504375] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 37.933 uM | PUBCHEM_BIOASSAY: qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2288, AID2289, AID2598, AID411] | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488771] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.